CytoSorbents Corporation reported a 3% revenue increase to $9.7 million in Q3 2026, driven by distributor sales growth and improved gross margins rising to 75%. The company reduced operating expenses by 11%, leading to a 59% improvement in operating loss and achieving operating cash flow breakeven excluding restructuring costs. Key growth drivers include expanding sales in Germany, advancing FDA approval for DrugSorb-ATR in the U.S., and leveraging the HemoDefend-BGA technology. CytoSorbents aims to sustain financial discipline while investing selectively to accelerate sales growth and unlock shareholder value through multiple strategic initiatives.
CytoSorbents Corporation's Q3 2026 financial results provide context for readers interested in health sector dynamics. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 05:21 WIB: out of 150 priced US health-sector stocks, 24 rose and 124 fell. Notable movers include RLAY at USD 18.16 with a 1-day change of -7.91%, FLNA at USD 0.44 with a 1-day change of -7.90%, and NUWE at USD 5.11 with a 1-day change of -7.59%.
Super League Enterprise, a company specializing in audience intelligence and media activation for the gaming industry, announced it will release its financial results for the third quarter ending September 30, 2026, on November 16, 2026, after market...
Stantec Inc. reported a 9.4% increase in net revenue to $1.9 billion for Q3 2026, driven by organic and acquisition growth. Adjusted EBITDA rose 16.6% to $377.1 million with a record margin of 20.2%, while adjusted EPS grew 23.5% to $1.89. The compan...
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
